| Clinical trials (indication, phase) | Date (year) |
| Protocol nb: E7080-G000-604 EISAI An open-label, multi-center, roll-over study to assess long term safety of Lenvatinib monotherapy or Lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored Lenvatinib trials | 2016 – 2022 2 patients |
| STUDY No. TST-EFS-04-MPP/16 Mattern Efficacy and safety of two- or three-times daily intranasal administration of testosterone gel (Tescum) in adult hypogonadal male patients, divided in 2 cohorts (cohort 1 – efficacy and long term safety assessment, cohort 2 – long term safety assessment) | 2017- 2020 40 patients randomized |
| Protocol nb: XL184–401 EXELIXIS A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | 2018 – 13 patients randomized |
| Protocol Nb: COR-2017-01 Cortendo AB A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | 2018- 2021 4 patients randomized |
| Protocol 112025-002 HRA Pharma Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks | 2019- 2022 1 patient |
| Protocol nb: XL184–311 EXELIXIS A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy | 2020- 2022 2 patients |
| Trial ID: EX9536-4388 Novo Nordisk Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) | 2020- 2022 3 patients |
| CORT125134-455 CORCEPT Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Efficacy and Safety of Relacorilant. | 2021- 2023 8 patients |
| CORT125134-456 CORCEPT Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant | 2021- 7 patients, recruiting |
| CORT125134-452 CORCEPT “An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome.” | 2021- 8 patients, recruiting |
| SPR001- 203 MEDPACE “A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPROO 1 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia” | 2023- 1 patient |
| SPR001- 204 MEDPACE “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia”” | 2023- 3 patients |
| SPI-62-CL-2001 Sparrow Pharmaceuticals, Inc “SPI-62 as a treatment for Adrenocorticotropic Hormone dependent Cushing’s Syndrome” | 2023- 1 patient, recruiting |
| SPI-62-CL-2002 Sparrow Pharmaceuticals, Inc “SPI-62 as a treatment for hypercortisolism related to a benign adrenal tumor” | 2023- recruiting |